SCHEMBL2776211

SCHEMBL2776211

Ic1ccc2c(c1)N(c1ccccc1)c1cc(Nc3ccc4c(c3)N(c3ccccc3)c3cc(I)ccc3N4)ccc1N2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNG2 P59768 2/20 1.00
GNB1 P62873 2/20 1.00
ALDH1A1 P00352 5/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2D6 P10635 1/20 0.69
PGR P06401 1/20 0.35
HSP90AA1 P07900 1/20 0.34
APP P05067 2/20 0.33
CHRM1 P11229 1/20 0.33
MEN1 O00255 1/20 0.32
AR P10275 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
GRK5 P34947 1/20 0.31
TYRO3 Q06418 1/20 0.31
DYRK1B Q9Y463 1/20 0.31
HSD17B10 Q99714 2/20 0.31
CYP3A4 P08684 1/20 0.31
HPGD P15428 1/20 0.31
CHEK1 O14757 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13320817 0.92 GNG2 (0.85) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL13320825 0.83 GNG2 (1.00) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL16556420 0.77 GNG2 (0.59) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL18102340 0.71 GNG2 (0.56) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL3903549 0.70 GNG2 (0.54) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL930322 0.70 GNG2 (0.53) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL23765023 0.69 GNG2 (0.53) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL30664408 0.69 GNG2 (0.53) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL2776491 0.69 GNG2 (0.53) GNG2GNB1ALDH1A1CYP1A2CYP2D6
SCHEMBL19001731 0.69 GNG2 (0.53) GNG2GNB1ALDH1A1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US claimed
US-20220220561-A1 METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT Advanced ReGen Medical Technologies, LLC 2022-07-14 US disclosed
WO-2020190888-A1 METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT Advanced ReGen Medical Technologies, LLC (US) 2020-09-24 WO disclosed
US-10717981-B2 Therapeutic compositions and methods of making and using the same Advanced ReGen Medical Technologies, LLC (US) 2020-07-21 US disclosed
WO-2019143847-A1 THERAPEUTIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME Advanced ReGen Medical Technologies, LLC (US) 2019-07-25 WO disclosed
US-20190218558-A1 THERAPEUTIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2019-07-18 US disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US disclosed
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US disclosed
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US disclosed
EP-2147310-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING University of Rochester (US) 2010-01-27 EP disclosed
WO-2009020677-A9 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIV ROCHESTER (US) 2009-04-16 WO disclosed
WO-2009020677-A9 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIV ROCHESTER (US) 2009-04-16 WO disclosed
WO-2009020677-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-02-12 WO disclosed
WO-2009020677-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717981-B2 Therapeutic compositions and methods of making and using the same PPM1F, PPM1A, PAX3 GNG2 1165/4885GNB1 748/4885ALDH1A1 4113/4885
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING GNAI1, GNAI3, GNAI2 GNG2 5/4885GNB1 4/4885ALDH1A1 4720/4885
US-20190218558-A1 THERAPEUTIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME PPM1F, PPM1A, PAX3 GNG2 1165/4885GNB1 748/4885ALDH1A1 4113/4885
US-20220220561-A1 METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT CD47, HAVCR2, BST2 GNG2 1936/4885GNB1 1570/4885ALDH1A1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.